Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

15.51 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 16, 2024

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Via Benzinga

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity ↗

April 16, 2024

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.

Via Benzinga

UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday ↗

April 16, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.

Via Benzinga

Topics Stocks

Cullinan Oncology: Q4 Earnings Insights ↗

March 14, 2024

Via Benzinga

Recap: Cullinan Oncology Q3 Earnings ↗

November 08, 2023

Via Benzinga

Analyst Ratings for Cullinan Oncology ↗

August 09, 2023

Via Benzinga

Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning

April 16, 2024

Via Investor Brand Network

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 16, 2024

Via Benzinga

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

April 16, 2024

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

April 16, 2024

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Analyst Ratings for Cullinan Oncology ↗

July 07, 2023

Via Benzinga

Analyst Expectations for Cullinan Oncology's Future ↗

June 15, 2023

Via Benzinga

Expert Ratings for Cullinan Oncology ↗

June 15, 2023

Via Benzinga

CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 ↗

March 14, 2024

CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 14, 2024

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

March 01, 2024

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

February 27, 2024

From Cullinan Oncology, Inc.

Via GlobeNewswire

Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗

January 30, 2024

Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter.

Via Benzinga

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

December 14, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 08, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

November 03, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

October 30, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

September 06, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗

October 06, 2023

Via Benzinga

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 10, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

August 09, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

July 31, 2023

From Cullinan Oncology, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

Why Shares of Cullinan Oncology Jumped This Week ↗

June 09, 2023

The company's presentation at a conference got the attention of analysts and investors.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.